万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>药学

Iranian Journal of Pharmaceutical Research《伊朗药学研究杂志》 (官网投稿)

简介
  • 期刊简称IRAN J PHARM RES
  • 参考译名《伊朗药学研究杂志》
  • 核心类别 SCIE(2024版), 外文期刊,
  • IF影响因子
  • 自引率
  • 主要研究方向医学-PHARMACOLOGY & PHARMACY 药学

主要研究方向:

等待设置主要研究方向
医学-PHARMACOLOGY & PHARMACY 药学

Iranian Journal of Pharmaceutical Research《伊朗药学研究杂志》(季刊). The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-discipli...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿

2期刊网址:http://ijpr.sbmu.ac.ir/

3投稿网址:http://ijpr.sbmu.ac.ir/author

4、官网邮箱:ijpr@sbmu.ac.ir

5、官网电话:+98-21-88873703

6、期刊刊期:季刊,一年出版4期。

2021年8月20日星期

                                 

 

投稿须知【官网信息】

 

Instructions for Authors updated September 2020

Introduction

The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-disciplinary pharmaceutical publication published quarterly to serve as a means for scientific information exchange in the international pharmaceutical forum. It accepts submission of original research not published or under consideration for publication anywhere else. Specific topics of interest to the journal include, but not limited to: pharmaceutics, industrial pharmacy, pharmacognosy, toxicology, medicinal chemistry, radiopharmacy, novel analytical methods for drug characterization, computational and modeling approaches to drug design, bio-medical experience, clinical investigation, rational drug prescribing, pharmacoeconomics, pharmacoepidemiology, pharmaceutical policy, pharma management, biotechnology, nanotechnology, biopharmaceutics and physical pharmacy. The paper must report novel findings based on an extensive and thorough study. Papers with didactic orientation, bulletins and subjects of exclusively local interest will not be considered for publication.

Full Disclosure

The manuscript should provide full and appropriate credit to all who contributed to the experimental data and their interpretation and discussion. Each manuscript must be accompanied by a cover letter signed by the corresponding author on behalf of all the authors that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out. The cover letter should explicitly state that the manuscript has not been previously published in any language anywhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and that it is not under simultaneous consideration by another journal. Moreover, Iranian Journal of Pharmaceutical Research will not publish any manuscript unless the chemical structures of all compounds are fully disclosed, either by reference to prior work providing such data or by enclosure of such data in the manuscript.

Copyright Transfer

A statement transferring copyright from the authors (or their employers, if they hold the copyright) to School of Pharmacy, Shahid Beheshti University of Medical Sciences will be required before the manuscript can be accepted for publication.

All the articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g. as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic databases, video disks, etc. without first obtaining written permission from the publisher. The use of general descriptive names, trade names, trademarks, in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Ethics in Animal and Clinical Investigations

Investigation using experimental animals must contain a statement confirming the adherence of the research to the ethics guidelines of the institute. Investigation involving human subjects should be in accordance with the Helsinki Declaration of 1975 (revised in 2008) and be approved by the institutional ethics committee or equivalent; and this should be stated in the “Methods” section.

In case of any doubt about the adherence of the research to the Helsinki Declaration, it should be demonstrated that the doubtful aspects have been explicitly approved by the relevant institutional ethics committee, and the rational for the approach should be explained.

In clinical studies involving human subjects, the patient’s right to privacy should be considered and any form of identifying information should not be published unless this is necessary for scientific purposes and the patient gives written informed consent. In this case, this should be indicated in the manuscript. Manuscripts reporting clinical trial data should provide the registration number of the study in the text of the manuscript.

……

更多详情:

http://ijpr.sbmu.ac.ir/journal/authors.note


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭